Results 21 to 30 of about 36,022 (296)

Attenuated secretion of glucose-dependent insulinotropic polypeptide (GIP) does not alleviate hyperphagic obesity and insulin resistance in ob/ob mice

Molecular Metabolism, 2017
Objective: Glucose-dependent insulinotropic polypeptide (GIP) is released during meals and promotes nutrient uptake and storage. GIP receptor knockout mice are protected from diet induced weight gain and thus GIP antagonists have been proposed as a ...
Satoko Shimazu-Kuwahara, Norio Harada, Shunsuke Yamane, Erina Joo, Akiko Sankoda, Timothy J. Kieffer, Nobuya Inagaki   +6 more
doaj   +1 more source

Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects

Physiological Reports, 2020
The short‐form glucose‐dependent insulinotropic polypeptide (GIP) (1–30) is released from islet alpha cells and promotes insulin secretion in a paracrine manner in vitro. However, it is not well elucidated how GIP (1–30) is involved in glucose metabolism
Yasutaka Takeda, Yukihiro Fujita, Tsuyoshi Yanagimachi, Nobuhiro Maruyama, Ryoichi Bessho, Hidemitsu Sakagami, Jun Honjo, Hiroki Yokoyama, Masakazu Haneda   +8 more
doaj   +1 more source

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP

Drug Design, Development and Therapy, 2022
Lijing Wang College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Lijing Wang, College of Life Science and Technology, China Pharmaceutical University, 639 Longmian ...
Wang L
doaj  

Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time

Alzheimer’s Research & Therapy, 2019
Background Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer’s disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a memory clinic, by assessing the ...
Elizabeth Kuhn, Inès Moulinet, Audrey Perrotin, Renaud La Joie, Brigitte Landeau, Clémence Tomadesso, Alexandre Bejanin, Siya Sherif, Vincent De La Sayette, Béatrice Desgranges, Denis Vivien, Géraldine Poisnel, Gaëlle Chételat   +12 more
doaj   +1 more source

A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. [PDF]

PLoS ONE, 2010
AIMS:The gastrointestinal hormone GIP promotes pancreatic islet function and exerts pro-survival actions on cultured beta-cells. However, GIP also promotes lipogenesis, thus potentially restricting its therapeutic use.
Scott B Widenmaier, Su-Jin Kim, Gary K Yang, Thomas De Los Reyes, Cuilan Nian, Ali Asadi, Yutaka Seino, Timothy J Kieffer, Yin Nam Kwok, Christopher H S McIntosh   +9 more
doaj   +1 more source

GIP-1 is required for a subset of dynamic microtubules at the apical ncMTOC.

, 2018
(A) Projected 1.5 μm optical sections through the E16 intestinal primordium show EBP-2/EB1::GFP localization in live bean-stage embryos of indicated genotypes.
Taylor D. Skokan (5597939), Jessica L. Feldman (175808), Maria D. Sallee (5597933), Brian C. Raftrey (5597942), Jennifer C. Zonka (5597936)   +4 more
core   +1 more source

Dose- and time-dependent effects of the dual GIP/GLP-1 receptor agonist tirzepatide on emotional overeating in a rat model of intracranial self-stimulation

Acta Biomedica Scientifica
Background. Despite the increasing prevalence of emotional overeating and obesity, the specific neurohormonal mechanisms involved in the pathogenesis of these pathological processes remain poorly understood.
N. S. Dedanishvili, S. S. Pyurveev, T. V. Brus, A. G. Vasiliev   +3 more
doaj   +1 more source

The naturally occurring GIP(1-30)NH₂ is a GIP receptor agonist in humans

, 2023
OBJECTIVE: The gut hormone glucose-dependent insulinotropic polypeptide (GIP) is an important regulator of glucose and bone metabolism. In rodents, the naturally occurring GIP variant, GIP(1-30)NH2, has shown similar effects as full-length GIP (GIP(1-42))
Hartmann, Bolette, Bergmann, Natasha C, Joachim Størling, Natasha C Bergmann, Holst, Jens J, Bolette Hartmann, Jens J Holst, Signe Stensen, Lærke S Gasbjerg, Krogh, Liva S L, Kristine Henriksen, Kirsa Skov-Jeppesen, Henriksen, Kristine, Rosenkilde, Mette M, Gasbjerg, Lærke S, Stensen, Signe, Knop, Filip K, Filip K Knop, Størling, Joachim, Skov-Jeppesen, Kirsa, Liva S L Krogh, Mette M Rosenkilde   +21 more
core   +1 more source

The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection

Frontiers in Endocrinology, 2022
The intestinal hormone, glucose-dependent insulinotropic polypeptide (GIP), is involved in important physiological functions, including postprandial blood glucose homeostasis, bone remodeling, and lipid metabolism.
Peter Lindquist, Lærke Smidt Gasbjerg, Jacek Mokrosinski, Jens Juul Holst, Jens Juul Holst, Alexander Sebastian Hauser, Mette Marie Rosenkilde   +6 more
doaj   +1 more source

Glucose-dependent insulinotropic polypeptide - a new link in the development of obesity

Ожирение и метаболизм, 2015
Objective. Glucose-dependent insulinotropic polypeptide (GIP) as well as glucagon-like peptide-1 (GLP-1) is intestinal incretin hormone that stimulates insulin secretion in response to feeding. Much evidence of GIP contribution to obesity development has
Ekaterina Alekseevna Shestakova, Aleksandr Victorovich Il'in, Marina Vladimirovna Shestakova, Ivan Ivanovich Dedov   +3 more
doaj   +1 more source